Guiding Treatment Strategies: The Role of Adjuvant Anti-Her2 Neu Therapy and Skin/Nipple Involvement in Local Recurrence-Free Survival in Breast Cancer Patients

Joe Omatoi, Abdul M Mohammed, Dennis Trujillo
1/4/2025
stat.APcs.LG

No confident code implementation found for this paper.

Abstract

This study explores how causal inference models, specifically the Linear Non-Gaussian Acyclic Model (LiNGAM), can extract causal relationships between demographic factors, treatments, conditions, and outcomes from observational patient data, enabling insights beyond correlation. Unlike traditional randomized controlled trials (RCTs), which establish causal relationships within narrowly defined populations, our method leverages broader observational data, improving generalizability. Using over 40 features in the Duke MRI Breast Cancer dataset, we found that Adjuvant Anti-Her2 Neu Therapy increased local recurrence-free survival by 169 days, while Skin/Nipple involvement reduced it by 351 days. These findings highlight the therapy's importance for Her2-positive patients and the need for targeted interventions for high-risk cases, informing personalized treatment strategies.

View on arXivView PDF

Code Implementations

No confident code match yet

We couldn't find an author-owned or strongly-evidenced community implementation for this paper. Any repos shown below are weak matches — verify before relying on them.

No code implementations found yet.

Know of an implementation? Let us know in the comments below!

Similar Papers

Cite this paper

@article{omatoi2025guiding,
  title  = {Guiding Treatment Strategies: The Role of Adjuvant Anti-Her2 Neu Therapy and Skin/Nipple Involvement in Local Recurrence-Free Survival in Breast Cancer Patients},
  author = {Joe Omatoi and Abdul M Mohammed and Dennis Trujillo},
  year   = {2025},
  eprint = {2501.04724},
  archivePrefix = {arXiv},
  url    = {http://arxiv.org/abs/2501.04724v1}
}

Add a badge to your README

Shows whether official code is linked for this paper.

Code of Paper badge
[![Code of Paper](https://codeofpaper.com/badge/2501.04724.svg)](https://codeofpaper.com/paper/2501.04724)

Discussion